For Healthcare Professionals

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

clipboard-pencil

About the study

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II dose (RP2D) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  2. Diagnosis of R/R MM per IMWG criteria
  3. For female participants of childbearing potential: agreement to remain abstinent or use contraception
  4. For male participants: agreement to remain abstinent or use a condom

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Prior treatment with cevostamab or another agent targeting fragment crystallizable receptor-like 5 (FcRH5)
  2. Prior treatment with elranatamab
  3. Prior allogeneic stem cell transplantation (SCT)
  4. Absolute plasma cell count exceeding 500 per milliliter (mL) or 5% of the peripheral blood white cells
  5. Diagnosis of Waldenström macroglobulinemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome
  6. Participants with known history of amyloidosis
  7. History of autoimmune disease
  8. History of confirmed progressive multifocal leukoencephalopathy
  9. Peripheral motor polyneuropathy of prespecified grade
  10. Known or suspected chronic cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) infection
  11. Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
  12. Acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  13. Human immunodeficiency virus (HIV) seropositivity
  14. History of central nervous system (CNS) myeloma disease
  15. Significant cardiovascular disease
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 888-662-6728 (U.S. Only)Email iconEmail Study Center

Study Details


Contition

Relapsed or Refractory Multiple Myeloma

Age

18+

Phase

PHASE1

Participants Needed

120

Est. Completion Date

Jul 31, 2026

Treatment Type

INTERVENTIONAL


Sponsor

Genentech, Inc.

ClinicalTrials.gov NCT Identifier

NCT05927571

Study Number

GO43979

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.